Publications by authors named "Shotaro Kondoh"
Background: A previous clinical trial for autoimmune pulmonary alveolar proteinosis (APAP) demonstrated that granulocyte-macrophage colony-stimulating factor (GM-CSF) inhalation reduced the mean density of the lung field on computed tomography (CT) across 18 axial slice planes at a two-dimensional level. In contrast, in this study, we challenged three-dimensional analysis for changes in CT density distribution using the same datasets.
Methods: As a sub-study of the trial, CT data of 31 and 27 patients who received GM-CSF and placebo, respectively, were analyzed.
Article Synopsis
- - Recent findings show that inhaling granulocyte-macrophage colony-stimulating factor (GM-CSF) may effectively treat mild to moderate autoimmune pulmonary alveolar proteinosis (aPAP), prompting the need for accurate measurement of GM-CSF autoantibodies (GMAb) to determine treatment eligibility.
- - A new high-performance GMAb testing kit was developed, significantly minimizing nonspecific binding in tests and demonstrating perfect predictive ability in distinguishing aPAP patients from healthy individuals with a specific cutoff value.
- - Validation of the testing kit showed impressive results with 97.6% specificity and 100% sensitivity in a larger sample group, confirming its effectiveness for diagnosing aPAP and differentiating it from other lung conditions
Background: Pulmonary alveolar proteinosis is a disease characterized by abnormal accumulation of surfactant in the alveoli. Most cases are autoimmune and are associated with an autoantibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) that prevents clearing of pulmonary surfactant by alveolar macrophages. An open-label, phase 2 study showed some therapeutic efficacy of inhaled recombinant human GM-CSF in patients with severe pulmonary alveolar proteinosis; however, the efficacy in patients with mild-to-moderate disease remains unclear.
View Article and Find Full Text PDF